Source:http://linkedlifedata.com/resource/pubmed/id/21224533
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
12
|
pubmed:dateCreated |
2011-1-12
|
pubmed:abstractText |
Serum CRP has been shown to be associated with the progression of esophageal cancer. The purpose of this study was to examine the relationship between treatment response and serum CRP levels in time course during definitive chemoradiotherapy (CRT) in terms of early prediction of CRT response by serum CRP. The subjects of this study were 36 patients with cT3/cT4 esophageal squamous cell carcinoma who underwent definitive CRT in our hospital. Serum CRP levels during definitive CRT (pretreatment, 1W, 2W and 3W after CRT initiation) were compared between CR and non-CR group. In addition, partition model was constructed to discriminate CR with non-CR and the prediction accuracy was evaluated. The patients were consisted of 28 males and 8 females. At pretreatment diagnosis, tumors were categorized as T3 (n=21) and T4 (n=15). Thirty four patients received FP-based chemotherapy and 2 patients received docetaxel-based chemotherapy. Treatment responses were categorized as CR (n=8), PR (n=14), NC (n=2) and PD (n=12). Serum CRP levels at the time of 2W after CRT initiation (CRT2W) in CR group were low compared to those in non-CR group (p=0.071). The partition model was constructed based on CRP levels at CRT2W. The prediction accuracies to discriminate CR from non-CR by CRP?0.1 were 50%, 82%, and 75% in sensitivity, specificity and accuracy, respectively. Serum CRP is a useful biomarker for an early prediction of CRT response.
|
pubmed:language |
jpn
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Biological Markers,
http://linkedlifedata.com/resource/pubmed/chemical/C-Reactive Protein,
http://linkedlifedata.com/resource/pubmed/chemical/Taxoids,
http://linkedlifedata.com/resource/pubmed/chemical/docetaxel
|
pubmed:status |
MEDLINE
|
pubmed:month |
Nov
|
pubmed:issn |
0385-0684
|
pubmed:author |
pubmed-author:FujiwaraHitoshiH,
pubmed-author:FurutaniAkinobuA,
pubmed-author:IchikawaDaisukeD,
pubmed-author:IkomaHisashiH,
pubmed-author:KokubaYukihitoY,
pubmed-author:KomatsuShuheiS,
pubmed-author:KuriuYoshiakiY,
pubmed-author:NakanishiMasayoshiM,
pubmed-author:OchiaiToshiyaT,
pubmed-author:OkamotoKazumaK,
pubmed-author:OkamuraHirokoH,
pubmed-author:OkamuraShinichiS,
pubmed-author:OtsujiEigoE,
pubmed-author:ShiozakiAtsushiA,
pubmed-author:SonoyamaTeruhisaT,
pubmed-author:TodoMomokoM,
pubmed-author:UmeharaSeijiS,
pubmed-author:YonedaMasayukiM
|
pubmed:issnType |
Print
|
pubmed:volume |
37
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
2237-9
|
pubmed:meshHeading |
pubmed-meshheading:21224533-Aged,
pubmed-meshheading:21224533-Aged, 80 and over,
pubmed-meshheading:21224533-Antineoplastic Agents,
pubmed-meshheading:21224533-Biological Markers,
pubmed-meshheading:21224533-C-Reactive Protein,
pubmed-meshheading:21224533-Carcinoma, Squamous Cell,
pubmed-meshheading:21224533-Combined Modality Therapy,
pubmed-meshheading:21224533-Disease Progression,
pubmed-meshheading:21224533-Esophageal Neoplasms,
pubmed-meshheading:21224533-Female,
pubmed-meshheading:21224533-Humans,
pubmed-meshheading:21224533-Male,
pubmed-meshheading:21224533-Middle Aged,
pubmed-meshheading:21224533-Retrospective Studies,
pubmed-meshheading:21224533-Sensitivity and Specificity,
pubmed-meshheading:21224533-Taxoids,
pubmed-meshheading:21224533-Treatment Outcome
|
pubmed:year |
2010
|
pubmed:articleTitle |
[Early prediction of treatment response by serum CRP levels in patients with advanced esophageal cancer who underwent definitive chemoradiotherapy].
|
pubmed:affiliation |
Division of Digestive Surgery, Dept. of Surgery, Kyoto Prefectural University of Medicine.
|
pubmed:publicationType |
Journal Article,
Comparative Study,
English Abstract
|